← All Legal Documents Consent Form

Informed Consent for Enhancement Procedures

Document Version: 4.2 Effective: 2025-01-01 Last Updated: 2026-02-01
Signature Required

This document must be signed before enhancement procedures. Review carefully with your Enhancement Specialist.

INFORMED CONSENT FOR HUMAN ENHANCEMENT PROCEDURES

Document Version: 4.2 Effective Date: January 1, 2025 Document ID: UL-LEGAL-IC-042

SECTION 1: PURPOSE AND SCOPE

1.1. This document constitutes the informed consent agreement between the undersigned individual (“Patient,” “You,” or “Recipient”) and Unzyme Laboratories Corporation (“Unzyme Laboratories,” “We,” “Us,” or “the Company”) regarding the enhancement procedure(s) specified in Schedule A attached hereto.

1.2. By signing this document, you acknowledge that you have been fully informed of the nature, risks, benefits, and alternatives to the proposed enhancement procedure(s), and that you voluntarily consent to proceed.

1.3. This consent applies to the initial procedure(s), all related maintenance procedures, firmware updates, and any necessary corrective interventions for the lifetime of the enhancement system(s).

SECTION 2: NATURE OF ENHANCEMENT PROCEDURES

2.1. Biological Integration. Enhancement procedures involve the permanent integration of synthetic components with your biological systems. This integration is designed to be irreversible under normal circumstances.

2.2. System Functionality. Enhanced systems will operate continuously unless manually deactivated, enter safe mode, or experience malfunction. Some systems perform background processes that may not be consciously perceptible.

2.3. Updates and Modifications. Unzyme Laboratories will periodically transmit firmware updates to your enhancement system(s). These updates are mandatory for system safety and may modify system behavior without additional consent requirements.

2.4. Monitoring and Diagnostics. Your enhancement system(s) will transmit diagnostic data to Unzyme Laboratories for quality assurance, safety monitoring, and product improvement purposes as detailed in Section 7.

SECTION 3: KNOWN RISKS AND COMPLICATIONS

3.1. Medical Risks. Enhancement procedures carry risks including but not limited to: infection, bleeding, nerve damage, organ damage, allergic reaction, chronic pain, scarring, disfigurement, disability, and death.

3.2. Integration Complications. Biological integration may result in: tissue rejection, chronic inflammation, immune system compromise, accelerated aging at integration sites, and systemic biological changes.

3.3. Functional Complications. Enhancement systems may experience: calibration errors, unexpected behavior, malfunction, premature failure, and incompatibility with future medical treatments.

3.4. Psychological Effects. Enhancement may produce psychological changes including but not limited to:

a) Altered emotional regulation and expression b) Changes to personality traits, preferences, or values c) Modified relationship patterns and social behaviors d) Adjustment of identity perception and self-concept e) Integration of enhancement-related thought patterns f) Dependency on enhancement functionality

3.5. Irreversibility. Most enhancement procedures cannot be reversed without significant risk of permanent damage, disability, or death. Reversal attempts are not recommended and may not be available.

3.6. Unknown Risks. Human enhancement technology is novel. Long-term effects beyond current study periods (5-10 years depending on product) are not fully characterized. You may experience effects not currently documented.

SECTION 4: ACKNOWLEDGMENT OF SPECIFIC RISKS

By signing this document, you specifically acknowledge understanding of:

4.1. Identity Continuity. Enhancement may change how you think, feel, and perceive yourself. The “you” following enhancement may differ meaningfully from the “you” consenting to this procedure. You accept this possibility as an inherent aspect of enhancement.

4.2. Relationship Impact. Enhancement may alter your relationships with unenhanced individuals, including family members, friends, and romantic partners. These changes may be unwanted by you or others and may be irreversible.

4.3. Autonomy Considerations. Enhancement systems may generate suggestions, impulses, or inclinations that influence your decisions. While you retain ultimate decision-making authority, the distinction between “your” decisions and enhancement-influenced decisions may become unclear.

4.4. Emergency Protocols. In emergency situations, Unzyme Laboratories may remotely access your enhancement system(s) to protect your safety or the safety of others, including system shutdown, functionality limitation, or other interventions.

4.5. Enhancement Community. Enhanced individuals often experience increased affinity for other enhanced individuals and decreased connection with unenhanced populations. This shift may not be consciously chosen.

SECTION 5: ALTERNATIVES TO ENHANCEMENT

5.1. You have been informed of alternatives to enhancement including:

a) No intervention (accepting current baseline function) b) Traditional medical treatments where applicable c) Non-invasive performance optimization methods d) Delayed enhancement pending additional research e) Partial or limited enhancement protocols

5.2. You have chosen to proceed with full enhancement despite available alternatives.

6.1. You may withdraw consent prior to the commencement of enhancement procedures by notifying your Enhancement Specialist in writing.

6.2. Once enhancement procedures have begun, withdrawal of consent may not be possible without completing the current procedural phase for safety reasons.

6.3. Post-enhancement withdrawal of consent is addressed in Section 3.5 (Irreversibility) and the Enhancement Discontinuation Policy.

SECTION 7: DATA COLLECTION AND USE

7.1. Your enhancement system(s) will collect and transmit data including but not limited to: biometric readings, system performance metrics, location data, usage patterns, and diagnostic information.

7.2. This data will be used for: safety monitoring, product improvement, regulatory compliance, research purposes, and service delivery.

7.3. Full data use policies are detailed in our Privacy Policy for Enhanced Individuals.

SECTION 8: INTELLECTUAL PROPERTY

8.1. All enhancement hardware, software, and firmware remain the intellectual property of Unzyme Laboratories.

8.2. Your enhancement does not constitute ownership of Unzyme Laboratories technology. Tampering with, reverse engineering, or unauthorized modification of enhancement systems is prohibited.

8.3. Biological materials removed during enhancement procedures become property of Unzyme Laboratories per the Biological Material Agreement.

SECTION 9: CERTIFICATION AND SIGNATURE

I, the undersigned, certify that:

  • I have read and understood this entire document
  • I have had opportunity to ask questions, and all questions have been answered satisfactorily
  • I understand the risks, including risks of identity change, relationship disruption, and irreversibility
  • I am entering into this consent voluntarily, without coercion or undue influence
  • I understand that signing this document means I accept all risks, known and unknown
  • I am of legal age and competent to provide consent

Patient Name: _________________________________

Patient Signature: _________________________________

Date: _________________________________

Witness Name: _________________________________

Witness Signature: _________________________________

Enhancement Specialist: _________________________________

Specialist Signature: _________________________________

This document constitutes a legally binding agreement. Retain a copy for your records. Questions regarding this consent may be directed to legal@unzymelaboratories.com.